Statement: In cohort 2 and 3 of the primary trial there was only case 1 of jaundice.
Primary_evidence: Adverse Events 1:   Total: 17/65 (26.15%)   Febrile neutropenia 3/65 (4.62%)   Neutropenia 2/65 (3.08%)   Pancytopenia 1/65 (1.54%)   Thrombocytopenia 1/65 (1.54%)   Cardiac arrest 2/65 (3.08%)   Myocardial infarction 1/65 (1.54%)   Diarrhoea 5/65 (7.69%)   Stomatitis 1/65 (1.54%)   Vomiting 2/65 (3.08%)   Fatigue 1/65 (1.54%)   Jaundice 1/65 (1.54%)   Neutropenic infection 2/65 (3.08%)